Data supporting mitochondrial morphological changes by SPG13-associated HSPD1 mutants

Yuki Miyamoto1, Funakoshi-Tago Megumi2, Nanami Hasegawa3

  • 1Department of Pharmacology, National Research Institute for Child Health and Development, Setagaya, Tokyo 157-8535, Japan.

Data in Brief
|February 23, 2016
PubMed

Insights

Mutations in the HSPD1 gene cause Spastic Paraplegia 13, leading to abnormal mitochondrial shape and function. This research investigates how these HSPD1 mutations impact mitochondrial dynamics and cell health.

Area of Science:

  • Cell Biology
  • Genetics
  • Neuroscience

Background:

  • Spastic Paraplegia 13 (SPG13) is linked to mutations in the HSPD1 gene.
  • Specific mutations, Val-98-to-Ile (V98I) and Gln-461-to-Glu (Q461E), are associated with SPG13.
  • HSPD1 encodes a mitochondrial protein crucial for mitochondrial function.

Purpose of the Study:

  • To investigate the impact of SPG13-associated HSPD1 mutations (V98I and Q461E) on mitochondrial morphology and function.
  • To understand the cellular mechanisms underlying HSPD1-related leukodystrophies.

Main Methods:

  • Transfection of Cos-7 cells with HSPD1 V98I and Q461E mutant genes.
  • Mitochondrial morphology assessment.
  • Mitochondrial membrane potential measurement using MitoTracker dye.

Main Results:

  • Both V98I and Q461E mutants resulted in an increased number of mitochondria.
  • Mutant HSPD1 proteins caused shorter mitochondrial lengths.
  • A decrease in mitochondrial membrane potential was observed in cells expressing either mutant.

Conclusions:

  • SPG13-associated HSPD1 mutations induce significant alterations in mitochondrial morphology.
  • These mutations lead to impaired mitochondrial function, evidenced by decreased membrane potential.
  • The findings suggest a role for HSPD1 mutations in aberrant mitochondrial dynamics contributing to HLD and SPG13 pathogenesis.